Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Upgraded by Zacks Research

Enlivex Therapeutics (NASDAQ:ENLV) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Tuesday,Zacks.com reports.

Several other brokerages have also recently weighed in on ENLV. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. Wall Street Zen raised shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 25th. Finally, HC Wainwright lifted their price objective on shares of Enlivex Therapeutics from $195.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Enlivex Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $247.50.

Enlivex Therapeutics Stock Performance

Shares of NASDAQ ENLV opened at $4.59 on Tuesday. The stock has a fifty day moving average price of $9.11 and a two-hundred day moving average price of $12.85. The firm has a market cap of $77.25 million, a P/E ratio of -0.56 and a beta of 1.52. Enlivex Therapeutics has a 1 year low of $4.25 and a 1 year high of $31.50.

Hedge Funds Weigh In On Enlivex Therapeutics

Hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its stake in Enlivex Therapeutics by 99.4% during the fourth quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after buying an additional 156,336 shares in the last quarter. HRT Financial LP boosted its holdings in shares of Enlivex Therapeutics by 719.4% in the fourth quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after buying an additional 135,198 shares during the period. Jane Street Group LLC increased its position in shares of Enlivex Therapeutics by 527.4% in the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after acquiring an additional 67,886 shares in the last quarter. Invesco Ltd. purchased a new position in shares of Enlivex Therapeutics in the fourth quarter worth approximately $43,000. Finally, Susquehanna International Group LLP acquired a new stake in shares of Enlivex Therapeutics during the third quarter valued at approximately $57,000. 1.02% of the stock is currently owned by institutional investors and hedge funds.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.